Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatmenthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment


Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of

Santhera: Endgültiger Studienstopp von DMD-Medikament
Santhera: Endgültiger Studienstopp von DMD-Medikament

Dämpfer für Santhera Pharmaceuticals (WKN: A0LCUK): Die Schweizer Biotechschmiede stellt die zulassungsrelevante Phase-3-Studie mit Puldysa bei Patienten mit Duchenne-Muskeldystrophie (DMD) ein. Die

NanoString Technologies Provides Preliminary Financial and Operational Highlights for Third Quarter 2020: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Provides Preliminary Financial and Operational Highlights for Third Quarter 2020


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today provided preliminary financial and operational highlights for

NanoString Technologies Announces Commencement of Public Offering of Common Stock: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Announces Commencement of Public Offering of Common Stock


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that it intends to offer and sell, subject to market

Medigene AG: Medigene expands patent protection of its technologies
Medigene AG: Medigene expands patent protection of its technologies

 

Planegg/Martinsried (06.10.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has

Medigene AG: Medigene weitet Patentschutz ihrer Technologien aus
Medigene AG: Medigene weitet Patentschutz ihrer Technologien aus

Planegg/Martinsried (06.10.2020) - Der Medigene AG (Medigene, FWB: MDG1, Prime Standard), einem Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die Entwicklung

Global Survey Shows Industrywide Priority to Modernize Clinical Trials for Faster Study Execution
Global Survey Shows Industrywide Priority to Modernize Clinical Trials for Faster Study Execution


Modernizing clinical trial operations is a top priority among life sciences companies according to the Veeva 2020 Unified Clinical Operations Survey Report, one of the largest-ever global surveys

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader

True Leaf Files Proposals to Exit Bankruptcy and Provides Status Update on Audited Year End Financial Statements
True Leaf Files Proposals to Exit Bankruptcy and Provides Status Update on Audited Year End Financial Statements

Vernon, BC - October 5, 2020 - True Leaf Brands Inc. (CSE: MJ) (OTC Pink: TRLFF) (FSE: TLA) (True Leaf or the “Company) is providing an update on its restructuring process and this

True Leaf reicht Vorschläge für Ausstieg aus dem Insolvenzverfahren ein und berichtet über den aktuellen Stand des geprüften Jahresabschlusses
True Leaf reicht Vorschläge für Ausstieg aus dem Insolvenzverfahren ein und berichtet über den aktuellen Stand des geprüften Jahresabschlusses

 

Vernon (British Columbia), 5. Oktober 2020. True Leaf Brands Inc. (CSE: MJ) (OTCQX: TRLFF) (FWB: TLA) (True Leaf oder das „Unternehmen) berichtet über den aktuellen Stand seines

AMN Healthcare Announces Pricing of Senior Notes Offering
AMN Healthcare Announces Pricing of Senior Notes Offering


AMN Healthcare Services, Inc. (NYSE: AMN) announced today that its wholly owned subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of $350.0 million aggregate

QIAGEN vervollständigt COVID-19 Testportfolio mit neuem Test-Kit zur Vereinfachung und Beschleunigung von PCR-Analysen in der Forschung
QIAGEN vervollständigt COVID-19 Testportfolio mit neuem Test-Kit zur Vereinfachung und Beschleunigung von PCR-Analysen in der Forschung


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, einen neuen optimierten Ansatz auf dem Gebiet der Epidemiologie von RNA-Viren einführen zu wollen, durch den die PCR-Analyse

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive, hormone receptor-positive (HR+), early stage breast cancer (eBC)

QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications
QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications


QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a novel straightforward approach to viral RNA epidemiology that will significantly simplify and accelerate PCR

Centura Health and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Colorado Springs: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Centura Health and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Colorado Springs


Centura Health and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement in Colorado Springs, expanding access to care for Humana Medicare members.

Grand View Health and Humana Sign Medicare Network Agreement in Pennsylvania: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Grand View Health and Humana Sign Medicare Network Agreement in Pennsylvania


Community health system Grand View Health and leading health and well-being company Humana Inc. (NYSE: HUM) have signed an agreement that will provide in-network access for Humana Medicare

VALBIOTIS in den EnterNext© PEA-PME 150 Index der Euronext Paris aufgenommen: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
VALBIOTIS in den EnterNext© PEA-PME 150 Index der Euronext Paris aufgenommen


VALBIOTIS (Paris: ALVAL) (Euronext: ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechselkrankheiten

Top FDA Official, Amy Abernethy, to Keynote Veeva R&D and Quality Summit Online
Top FDA Official, Amy Abernethy, to Keynote Veeva R&D and Quality Summit Online


Veeva Systems (NYSE: VEEV) today announced that Amy Abernethy, MD, PhD, principal deputy commissioner of the FDA, is the featured keynote at the 2020 Veeva R&D and Quality Summit Online. In a

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash


Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or

AMN Healthcare Names Rear Admiral Sylvia Trent-Adams to Board of Directors
AMN Healthcare Names Rear Admiral Sylvia Trent-Adams to Board of Directors


AMN Healthcare (NYSE:AMN) announces the appointment to its Board of Directors of Rear Admiral Sylvia Trent-Adams, PhD, RN, FAAN, a distinguished leader in the U.S. Public Health Service

NanoString to Release Third Quarter 2020 Operating Results and Host Conference Call on Monday, November 9, 2020: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Release Third Quarter 2020 Operating Results and Host Conference Call on Monday, November 9, 2020


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will release third quarter 2020

VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris


Regulatory News:



VALBIOTIS (Paris:ALVAL) (Euronext: ALVAL), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it

Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19
Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19


Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today